A Multi-Center, Open-Label, Dose-Escalation Study to Evaluate the Safety, Efficacy, and Exposure to TRM-1 (Fully Human Monoclonal Antibody to the TRAIL-R1) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma.

Trial Profile

A Multi-Center, Open-Label, Dose-Escalation Study to Evaluate the Safety, Efficacy, and Exposure to TRM-1 (Fully Human Monoclonal Antibody to the TRAIL-R1) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2013

At a glance

  • Drugs Mapatumumab (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Mar 2012 Actual end date (May 2007) added as reported by ClinicalTrials.gov.
    • 21 Nov 2009 Actual initiation date (28 Jun 2004) and patient number (14) added as reported by M.D. Anderson Cancer Center record.
    • 21 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center, 2004-0087).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top